All In Biotech

Drug Trial Radar · NCT06688123

Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects

A Randomized, Open-label, Treat-to-target, Parallel-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-3167 and Insulin Glargine in Patients With Type 2 Diabetes Mellitus With Metformin Alone or in Combination With SGLT2 Inhibitors

Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 275 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

275

Actual

Start

Jan 8, 2025

Primary completion

Apr 22, 2026

Study completion Apr 22, 2026

Sponsor

Sponsor type
Industry
First posted
Nov 14, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of SHR-3167 compared with insulin glargine after treatment in insulin naïve subjects with type 2 diabetes treated with metformin alone or in combination with SGLT2 subjects.

Conditions

  • Type 2 Diabetes

Interventions

  • SHR-3167Drug

    Dose level 1.

  • SHR-3167Drug

    Dose level 2.

  • Insulin glargineDrug

    Dose level 3.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline to week 20 in HbA1c (HemoglobinA1c)Time frame: Week 0 to week 20.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Jiangsu Provincial People's Hospital

    Nanjing, Jiangsu, China

  • Shanghai Sixth People's Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.